Pharmacoproteomic Analysis of Prechemotherapy and Postchemotherapy Plasma Samples from Patients Receiving Neoadjuvant or Adjuvant Chemotherapy for Breast Carcinoma

Cancer

Volumn 100, Issue 9, 2004, Pages 1814-1822

  Pusztai, Lajos ^a   Gregory, Betsy W ^b   Baggerly, Keith A ^a   Peng, Bo ^c   Koomen, John ^a   Kuerer, Henry M ^a   Esteva, Francisco J ^a   Symmans, W Fraser ^a   Wagner, Peter ^a   Hortobagyi, Gabriel N ^a   Laronga, Christine ^b   Semmes, O John ^b   Wright Jr , George L ^b   Drake, Richard R ^b   Vlahou, Antonia ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c Rice University   (United States)

Author keywords

Biomarkers; Paclitaxel; Preoperative chemotherapy; Proteomics; SELDI MS

Indexed keywords

CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; FLUOROURACIL; LORAZEPAM; ONDANSETRON; PACLITAXEL; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DESORPTION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEOMICS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROTEOMICS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 11144355338     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20203     Document Type: Article

References (17)

1. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359:572-577.
2. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 2003;9:2904-2911.
3. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002;62:3609-3614.
4. Vlahou A, Laronga C, Wilson L, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer. 2003;4:203-209.
5. Vlahou A, Schorge J, Gregory BW, Coleman R. Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J Biomed Biotechnol. 2003;2003:308-314.
6. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002;48: 1296-1304.
7. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of bladder cancer. Am J Pathol. 2001;158:1491-1502.
8. Kuerer HM, Goldknopf IL, Fritsche H, Krishnamurthy S, Sheta EA, Hunt KK. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer. 2002;95:2276-2282.
9. Varnum SM, Covington CC, Woodbury RL, et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat. 2003;80:87-97.
10. Dwek MV, Alaiya AA. Proteome analysis enables separate clustering of normal breast, benign breast and breast cancer tissues. Br J Cancer. 2003;89:305-307.
11. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet. 2003; 362:433-439.
12. Chen ST, Pan TL, Tsai YC, Huang CM. Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett. 2002;181:95-107.
13. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res. 2000;6:4610-4617.
14. Coombes KR, Fritsche HA, Clarke C, et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid using surface enhanced laser desorption and ionization. Clin Chem. 2003;49:1615-1623.
15. Swiss Institute of Bioinformatics. ExPASy molecular biology server [databse online]. Available from URL: http://us. expasy.org/ [accessed May 2003].
16. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783-788.
17. Tashima LS, Hieber AD, Greenwood FC, Bryant-Greenwood GD. The human Leydig insulin-like (hLEY l-L) gene is expressed in the corpus luteum and trophoblast. J Clin Endocrinol Metab. 1995;80:707-710.